Literature DB >> 31539141

LncRNA TUG1 inhibits the proliferation and fibrosis of mesangial cells in diabetic nephropathy via inhibiting the PI3K/AKT pathway.

X-J Zang1, L Li, X Du, B Yang, C-L Mei.   

Abstract

OBJECTIVE: To elucidate the potential function of long non-coding RNA (lncRNA) TUG1 in the progression of diabetic nephropathy (DN) and the underlying mechanism.
MATERIALS AND METHODS: Rat diabetes mellitus (DM) model was established by streptozocin (STZ) administration. In vivo levels of TUG1 and relative genes in the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway in DM rats and control rats were determined by the quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Moreover, levels of kidney weight, 24 h-urine protein, blood urea nitrogen and serum creatinine in DM rats and controls were detected. Mesangial cells were subjected to induction of high-level glucose. Relative levels of TUG1 and relative genes in the PI3K/AKT pathway in mesangial cells were determined as well. Through Cell Counting Kit-8 (CCK-8) and 5-Ethynyl-2'-deoxyuridine (EdU) assay, the regulatory effect of TUG1 on the proliferative ability of mesangial cells induced with high-level glucose was evaluated. Finally, expression changes in the PI3K/AKT pathway and extracellular matrix (ECM)-related genes in mesangial cells were determined.
RESULTS: TUG1 was downregulated in DM rats and mesangial cells induced with high-level glucose. Compared with controls, DM rats presented higher levels of kidney weight, 24 h-urine protein, blood urea nitrogen and serum creatinine, which were markedly reduced after TUG1 overexpression in vivo. Moreover, overexpression of TUG1 downregulated TGF-β1, FN, and COL-IV, and inhibited the activation of the PI3K/AKT pathway.
CONCLUSIONS: TUG1 is downregulated in DN. The overexpression of TUG1 could suppress the proliferation and ECM accumulation of mesangial cells via inhibiting the PI3K/AKT pathway.

Entities:  

Year:  2019        PMID: 31539141     DOI: 10.26355/eurrev_201909_18867

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

Review 1.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

2.  LncRNA TUG1 exhibits pro-fibrosis activity in hypertrophic scar through TAK1/YAP/TAZ pathway via miR-27b-3p.

Authors:  Xian-Min Li; Wen-Yuan Yu; Qi Chen; Hui-Ru Zhuang; Su-Yue Gao; Tian-Lan Zhao
Journal:  Mol Cell Biochem       Date:  2021-03-31       Impact factor: 3.396

3.  Expression of LncRNA KCNQ1Ot1 in diabetic nephropathy and its correlation with MEK/ERK signaling pathway.

Authors:  Xuangeng Huang; Junhua Tan; Yingrong Li; Hongye Su; Meiying Huang; Feifan Huang; Peng Huang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

4.  LncRNA KCNQ1OT1 affects cell proliferation, apoptosis and fibrosis through regulating miR-18b-5p/SORBS2 axis and NF-ĸB pathway in diabetic nephropathy.

Authors:  Ran Jie; Pengpeng Zhu; Jiao Zhong; Yan Zhang; Hongyan Wu
Journal:  Diabetol Metab Syndr       Date:  2020-09-03       Impact factor: 3.320

Review 5.  Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.

Authors:  Mohammad Rafi Khezri; Naime Majidi Zolbanin; Morteza Ghasemnejad-Berenji; Reza Jafari
Journal:  Eur J Pharmacol       Date:  2021-05-17       Impact factor: 5.195

6.  Construction and Bioinformatics Analysis of the miRNA-mRNA Regulatory Network in Diabetic Nephropathy.

Authors:  Yameng Li; Yukun Xu; Yawei Hou; Rui Li
Journal:  J Healthc Eng       Date:  2021-11-18       Impact factor: 2.682

7.  Differential Expression of Serum TUG1, LINC00657, miR-9, and miR-106a in Diabetic Patients With and Without Ischemic Stroke.

Authors:  Omayma O Abdelaleem; Olfat G Shaker; Mohamed M Mohamed; Tarek I Ahmed; Ahmed F Elkhateeb; Noha K Abdelghaffar; Naglaa A Ahmed; Abeer A Khalefa; Nada F Hemeda; Rania H Mahmoud
Journal:  Front Mol Biosci       Date:  2022-02-14

8.  TUG1 knockdown suppresses cardiac fibrosis after myocardial infarction.

Authors:  Qingsong Sun; Man Luo; Zhiwei Gao; Xiang Han; Zhuan Yan; Shouxiang Xie; Hongmei Zhao; Hong Sun
Journal:  Mamm Genome       Date:  2021-08-03       Impact factor: 2.957

Review 9.  Potential Roles of Long Noncoding RNAs as Therapeutic Targets in Renal Fibrosis.

Authors:  Hyun Jin Jung; Hyun-Ju Kim; Kwan-Kyu Park
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

10.  TUG1 enhances high glucose-impaired endothelial progenitor cell function via miR-29c-3p/PDGF-BB/Wnt signaling.

Authors:  Yang Li; Kangkang Zhi; Shilong Han; Xue Li; Maoquan Li; Weishuai Lian; Haijun Zhang; Xiaoping Zhang
Journal:  Stem Cell Res Ther       Date:  2020-10-15       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.